Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease
In this nationwide IBD cohort, there was not an increased risk of infection-related hospitalization among patients exposed to vedolizumab, ustekinumab, and tofacitinib as compared with patients on anti-TNF inhibitor and TP combination therapy and rates of infection-related hospitalization were low overall. These findings should guide clinical decision making and patient-physician discussions when selecting a therapeutic agent with the primary emphasis on efficacy.
Authors
- Manthankumar Patel (ORCID: https://orcid.org/0000-0001-6133-8660)
- Janak Bahirwani (ORCID: https://orcid.org/0000-0002-9150-521X)
- Dhruvan Patel (ORCID: https://orcid.org/0000-0001-5447-2415)
- Nadim Mahmud (ORCID: https://orcid.org/0000-0003-1889-3954)
- Ramaswamy Sundararajan (ORCID: https://orcid.org/0000-0002-9169-6036)
- Nabeel Khan (ORCID: https://orcid.org/0000-0002-5368-7518)
Institutions
- Philadelphia VA Medical Center (US)
- Mercy Fitzgerald Hospital (US)
- Kadlec Regional Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1093/ibd/izaf218
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82